Table 2.

Between-treatment analysis of change in BP at 4 weeks, 8 weeks, 4 months, and 8 months) from the baseline^a

Americas: RHTN only							Americas: all patients
	Placebo		Spiro				Placebo		Spiro
	n	LSM (SE)	n	LSM (SE)	Diff	P	n	LSM (SE)	n	LSM (SE)	Diff	P
Week 4
SBP	194	−7.78 (1.4)	180	−14.08 (1.4)	−6.29 (1.96)	0.001	824	0.72 (0.6)	843	−2.64 (0.6)	−3.36 (0.82)	<0.001
DBP	194	−3.09 (0.8)	180	−5.84 (0.8)	−2.75 (1.15)	0.02	824	−0.27 (0.4)	843	−1.89 (0.4)	−1.62 (0.51)	0.001
BP controlb	194	90 (46.4%)	180	114 (63.3%)	OR: 1.89 (1.23–2.89)	0.003	824	597 (72.5%)	843	655 (77.6%)	OR: 1.33 (1.05–1.68)	0.02
Week 8
SBP	193	−5.92 (2.00)	173	−15.62 (1.45)	−5.92 (2.00)	0.003	820	0.54 (0.6)	825	−4.18 (0.6)	−4.72 (0.82)	<0.001
DBP	193	−3.86 (0.83)	173	−7.07 (0.88)	−3.21 (1.21)	0.008	820	−0.18 (0.4)	825	−3.21 (0.4)	−3.03 (0.50)	<0.001
BP controlb	193	93 (48.2%)	173	116 (67.1%)	OR: 2.07 (1.33–3.19)	0.001	820	595 (72.6%)	825	663 (80.3%)	OR: 1.56 (1.23–1.99)	<0.001
Month 4
SBP	193	−9.54 (1.33)	173	−15.07 (1.41)	−5.53 (1.95)	0.005	809	0.94 (0.6)	820	−2.75 (0.6)	−3.69 (0.86)	<0.001
DBP	193	−4.33 (0.84)	173	−6.54 (0.88)	−2.21 (1.22)	0.07	809	−0.39 (0.4)	820	1.95 (0.4)	−1.56 (0.53)	0.003
BP controlb	193	93 (48.2%)	173	109 (63.0%)	OR: 1.77 (1.16–2.69)	0.008	809	570 (70.5%)	820	645 (78.6%)	OR: 1.55 (1.23–1.96)	<0.001
Month 8
SBP	174	−9.82 (1.48)	164	−15.65 (1.52)	−5.83 (2.12)	0.006	758	−2.23 (0.6)	779	−2.88 (0.6)	−5.11 (0.89)	<0.001
DBP	174	−4.33 (0.91)	164	−7.47 (0.93)	−3.14 (1.30)	0.016	758	0.57 (0.4)	779	−2.12 (0.4)	−2.69 (0.55)	<0.001
BP controlb	174	95 (54.6%)	164	110 (67.1%)	OR: 1.61 (1.03–2.52)	0.036	758	524 (69.1%)	779	609 (78.1%)	OR: 1.61 (1.27–2.04)	<0.001

Abbreviations: BP, blood pressure; DBP, diastolic BP; LSM, least square mean; OR, odds ratio; SBP, systolic BP.

^aAdjusted for baseline SBP and treatment.

^bBP control defined by SBP <140 mm Hg and DBP <90 mm Hg.